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Immunoscore has been shown to be a very powerful
prognositc indicator in patients with clinically localized
colorectal cancer, with no detectable tumour spread to
lymph nodes or distant organs. These patients are
usually treated with surgical removal of the tumour
only. However, approximately 25% of these patients will
have recurrence of their disease. No tumour-associated
marker to predict the recurrence of this subgroup of
patients and define who could benefit from adjuvant
therapy is used in clinical routine[1] In addition to
immunoscore, other parameters of the immune response
are investigated – mostly cellular immunity and the pro-
duction of immunosuppressive and neoangiogenic mar-
kers. Vascular endothelial growth factor (VEGF) is the
factor responsible for neoangiogenesis and it is being
considered as a possible prognostic marker of disease
progression. Transforming growth factor-beta (TGF-
beta) is also neoangiogenic and a highly immunosup-
pressive factor as it suppresses the body’s natural immu-
nity against tumours and is also being considered as
another possible prognostic marker of disease
progression.
Aim
To monitor the immune response in patients with stage
II colorectal cancer, with a focus on cellular as well as
humoral immunity. TGF-beta and VEGF levels were
followed.
Methods
38 patients with stage II colon cancer included in the
research project received routine cancer treatment. .
Basic parameters – histological type and grade,
proliferative markers – were established at baseline.
Patients were evaluated by a clinical immunooncologist
to exclude any immune disorders of allergic or autoim-
mune origin. TGF-beta and VEGF were measured using
ELISA, and anti-tumour cellular immunity (CD4, CD8,
T-reg, B cells) were measured via flow cytometry.
Results
In patients with stage II colorectal cancer, predomi-
nantly a depression in cellular immunity was seen.
Plasma levels of immunglobulins were also reduced,
particularly the IgG3 subtype. Most patients showed
some clinical symptoms of immunodeficiency, such as
frequent respiratory tract infections and/or herpetic
infections. TGF-beta and VEGF plasma levels were
increased.
Conclusion
The correlation of these neoangiogenic and immunosup-
pressive factors, as well as the state of anticancer immu-
nity, could help in the future as a prognostic marker
and contribute to the selection of targeted adjuvant as
well as immune therapy in patients with colorectal can-
cer stage II.
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